1260 related articles for article (PubMed ID: 24954834)
21. Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT.
Matsuda H
J Nucl Med; 2007 Aug; 48(8):1289-300. PubMed ID: 17631544
[TBL] [Abstract][Full Text] [Related]
22. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
23. [Differences of neuroimaging between early-onset and late-onset Alzheimer-type dementia].
Hanyu H; Nakano S; Abe S; Arai H; Iwamoto T; Takasaki M
Rinsho Shinkeigaku; 1995 Oct; 35(10):1104-9. PubMed ID: 8821493
[TBL] [Abstract][Full Text] [Related]
24. Effects of partial volume correction on discrimination between very early Alzheimer's dementia and controls using brain perfusion SPECT.
Kanetaka H; Matsuda H; Asada T; Ohnishi T; Yamashita F; Imabayashi E; Tanaka F; Nakano S; Takasaki M
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):975-80. PubMed ID: 14991240
[TBL] [Abstract][Full Text] [Related]
25. Prefrontal Lobe Brain Reserve Capacity with Resistance to Higher Global Amyloid Load and White Matter Hyperintensity Burden in Mild Stage Alzheimer's Disease.
Chang YT; Huang CW; Chen NC; Lin KJ; Huang SH; Chang YH; Hsu SW; Chang WN; Lui CC; Hsu CW; Chang CC
PLoS One; 2016; 11(2):e0149056. PubMed ID: 26872386
[TBL] [Abstract][Full Text] [Related]
26. Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β.
Maya Y; Okumura Y; Kobayashi R; Onishi T; Shoyama Y; Barret O; Alagille D; Jennings D; Marek K; Seibyl J; Tamagnan G; Tanaka A; Shirakami Y
Brain; 2016 Jan; 139(Pt 1):193-203. PubMed ID: 26490333
[TBL] [Abstract][Full Text] [Related]
27. Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer's disease correspond to dissociable functional brain networks.
Grothe MJ; Teipel SJ;
Hum Brain Mapp; 2016 Jan; 37(1):35-53. PubMed ID: 26441321
[TBL] [Abstract][Full Text] [Related]
28. Contribution of neuroimaging to the diagnosis of Alzheimer's disease and vascular dementia.
Román G; Pascual B
Arch Med Res; 2012 Nov; 43(8):671-6. PubMed ID: 23142262
[TBL] [Abstract][Full Text] [Related]
29. Neuroimaging in cerebrovascular disorders: measurement of cerebral physiology after stroke and assessment of stroke recovery.
Mountz JM; Liu HG; Deutsch G
Semin Nucl Med; 2003 Jan; 33(1):56-76. PubMed ID: 12605357
[TBL] [Abstract][Full Text] [Related]
30. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay.
Förster S; Grimmer T; Miederer I; Henriksen G; Yousefi BH; Graner P; Wester HJ; Förstl H; Kurz A; Dickerson BC; Bartenstein P; Drzezga A
Biol Psychiatry; 2012 May; 71(9):792-7. PubMed ID: 21679929
[TBL] [Abstract][Full Text] [Related]
31. White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients.
Zhou Y; Yu F; Duong TQ;
J Magn Reson Imaging; 2015 Jan; 41(1):102-9. PubMed ID: 24382798
[TBL] [Abstract][Full Text] [Related]
32. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
33. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
[TBL] [Abstract][Full Text] [Related]
34. Pitfalls of voxel-based amyloid PET analyses for diagnosis of Alzheimer's disease: artifacts due to non-specific uptake in the white matter and the skull.
Arai A; Kaneta T; Okamura N; Tashiro M; Iwata R; Takanami K; Fukuda H; Takahashi S; Yanai K; Kudo Y; Arai H
Tohoku J Exp Med; 2014 Nov; 234(3):175-81. PubMed ID: 25311079
[TBL] [Abstract][Full Text] [Related]
35. Amyloid deposition and CBF patterns predict conversion of mild cognitive impairment to dementia.
Kikukawa T; Abe T; Ataka S; Saito H; Hasegawa I; Mino T; Takeuchi J; Kawabe J; Wada Y; Watanabe Y; Itoh Y
Neurol Sci; 2018 Sep; 39(9):1597-1602. PubMed ID: 29936556
[TBL] [Abstract][Full Text] [Related]
36. Regional brain hypometabolism is unrelated to regional amyloid plaque burden.
Altmann A; Ng B; Landau SM; Jagust WJ; Greicius MD;
Brain; 2015 Dec; 138(Pt 12):3734-46. PubMed ID: 26419799
[TBL] [Abstract][Full Text] [Related]
37. Comparison of SPM and NEUROSTAT in voxelwise statistical analysis of brain SPECT and MRI at the early stage of Alzheimer's disease.
Nishimiya M; Matsuda H; Imabayashi E; Kuji I; Sato N
Ann Nucl Med; 2008 Dec; 22(10):921-7. PubMed ID: 19142712
[TBL] [Abstract][Full Text] [Related]
38. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
Yew B; Nation DA;
Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
[TBL] [Abstract][Full Text] [Related]
39. Regional cerebral blood flow differences in patients with mild cognitive impairment between those who did and did not develop Alzheimer's disease.
Park KW; Yoon HJ; Kang DY; Kim BC; Kim S; Kim JW
Psychiatry Res; 2012; 203(2-3):201-6. PubMed ID: 22980226
[TBL] [Abstract][Full Text] [Related]
40. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
